Praxis Precision Medicines, Inc. Announces FDA Acceptance of Priority Review for Relutrigine in SCN2A and SCN8A DEEs

Boston, MA, April 6, 2026 — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a biopharmaceutical company focused on developing precision medicines for central nervous system disorders, announced a significant regulatory milestone that is highly relevant to shareholders and the investment community.

Key Highlights

• FDA Accepts Priority Review:
  The U.S. Food and Drug Administration (FDA) has accepted Praxis’s New Drug Application (NDA) for relutrigine, a novel investigational therapy for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).
• Priority Review Status:
  The FDA has granted priority review status to the NDA, underscoring the agency’s recognition of the potential for relutrigine to address a critical unmet medical need in rare pediatric epileptic disorders.
• PDUFA Target Action Date:
  The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 27, 2026. This means that a final regulatory decision regarding the marketing approval of relutrigine could occur as soon as that date.
• Price-Sensitive Nature:
  This development may be highly price-sensitive, as FDA acceptance for priority review is generally seen as a major de-risking event by the market and accelerates the potential time to market for key pipeline assets.

What Investors and Shareholders Need to Know

• Potential Share Price Impact:
  The FDA’s acceptance of the NDA for priority review is a significant milestone in a drug development timeline. Such regulatory progress often triggers positive sentiment and can drive share price appreciation, particularly for companies with a clinical-stage or pre-commercial profile like Praxis Precision Medicines.
• Significance of Indication:
  SCN2A and SCN8A DEEs are rare, severe forms of early-onset epilepsy. There are currently no FDA-approved treatments specifically targeting these genetic epileptic encephalopathies, positioning relutrigine as a potential first-in-class therapy and offering substantial commercial opportunity if approved.
• Regulatory De-Risking:
  The FDA’s willingness to grant priority review signals regulatory confidence in both the clinical data submitted and the unmet medical need. It also shortens the review window, which can help Praxis accelerate its timeline to potential commercialization and revenue generation.
• Next Steps:
  Investors should watch for updates regarding the FDA review process, advisory committee meetings (if scheduled), and any communications from Praxis regarding commercial readiness or additional regulatory milestones.

Other Regulatory and Compliance Notes

• No Indication of Written or Soliciting Communications:
  Praxis Precision Medicines has indicated that this 8-K filing does not contain written communications under SEC Rule 425, nor does it constitute soliciting material under Rule 14a-12. The filing is strictly an update on a material business event.
• No Pre-commencement Communications:
  The company has also reported that the filing does not involve pre-commencement communications regarding tender offers under Rules 14d-2(b) or 13e-4(c).

Corporate Information

• Company Name: Praxis Precision Medicines, Inc.
• Address: 99 High Street, 30th Floor, Boston, MA 02110
• Trading Symbol: PRAX
• Exchange: Nasdaq Global Select Market
• CEO: Marcio Souza

Conclusion

The FDA’s acceptance of Praxis Precision Medicines’ NDA for relutrigine, with priority review for the treatment of SCN2A and SCN8A DEEs, marks a pivotal moment for the company. This regulatory progress could materially affect Praxis’s share price and valuation as it advances toward a potential commercial launch in a high-need therapeutic area. Investors should monitor further updates as the PDUFA decision date approaches.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information is based on a review of the official SEC filing and public disclosures as of April 6, 2026.

View Praxis Precision Medicines, Inc. Historical chart here